

Edoardo Spina

List of Publications by Citations

Source: <https://exaly.com/author-pdf/3597357/edoardo-spina-publications-by-citations.pdf>

Version: 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

262
papers

9,603
citations

57
h-index

85
g-index

291
ext. papers

10,782
ext. citations

4
avg, IF

6.07
L-index

#	Paper	IF	Citations
262	CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages. <i>Acta Psychiatrica Scandinavica</i> , 2001 , 104, 173-92	6.5	285
261	Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance. <i>Clinical Pharmacology and Therapeutics</i> , 2002 , 72, 702-10	6.1	272
260	Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: an update. <i>Clinical Therapeutics</i> , 2008 , 30, 1206-27	3.5	269
259	Clinically significant pharmacokinetic drug interactions with carbamazepine. An update. <i>Clinical Pharmacokinetics</i> , 1996 , 31, 198-214	6.2	236
258	Metabolic drug interactions with newer antipsychotics: a comparative review. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2007 , 100, 4-22	3.1	198
257	Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone. <i>Psychopharmacology</i> , 1999 , 147, 300-5	4.7	169
256	Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population. <i>Pharmacological Research</i> , 2004 , 50, 195-200	10.2	160
255	Quetiapine and clozapine in parkinsonian patients with dopaminergic psychosis. <i>Clinical Neuropharmacology</i> , 2004 , 27, 153-6	1.4	159
254	Genetic polymorphism of cytochrome P450 2C9 in a Caucasian and a black African population. <i>British Journal of Clinical Pharmacology</i> , 2001 , 52, 447-50	3.8	154
253	Antiepileptic drugs: indications other than epilepsy. <i>Epileptic Disorders</i> , 2004 , 6, 57-75	1.9	153
252	Metabolic drug interactions with new psychotropic agents. <i>Fundamental and Clinical Pharmacology</i> , 2003 , 17, 517-38	3.1	138
251	Relationship between plasma concentrations of clozapine and norclozapine and therapeutic response in patients with schizophrenia resistant to conventional neuroleptics. <i>Psychopharmacology</i> , 2000 , 148, 83-9	4.7	133
250	Effect of fluvoxamine on the pharmacokinetics of imipramine and desipramine in healthy subjects. <i>Therapeutic Drug Monitoring</i> , 1993 , 15, 243-6	3.2	126
249	Plasma concentrations of risperidone and 9-hydroxyrisperidone: effect of comedication with carbamazepine or valproate. <i>Therapeutic Drug Monitoring</i> , 2000 , 22, 481-5	3.2	113
248	Clinically significant drug interactions with newer antidepressants. <i>CNS Drugs</i> , 2012 , 26, 39-67	6.7	104
247	Relationship between plasma risperidone and 9-hydroxyrisperidone concentrations and clinical response in patients with schizophrenia. <i>Psychopharmacology</i> , 2001 , 153, 238-43	4.7	101
246	Clinically significant drug interactions with antidepressants in the elderly. <i>Drugs and Aging</i> , 2002 , 19, 299-320	4.7	101

245	Different enantioselective 9-hydroxylation of risperidone by the two human CYP2D6 and CYP3A4 enzymes. <i>Drug Metabolism and Disposition</i> , 2001 , 29, 1263-8	4	100
244	Clinical applications of CYP genotyping in psychiatry. <i>Journal of Neural Transmission</i> , 2015 , 122, 5-28	4.3	96
243	Age-related changes in pharmacodynamics: focus on drugs acting on central nervous and cardiovascular systems. <i>Current Drug Metabolism</i> , 2011 , 12, 611-20	3.5	95
242	Plasma concentrations of risperidone and 9-hydroxyrisperidone during combined treatment with paroxetine. <i>Therapeutic Drug Monitoring</i> , 2001 , 23, 223-7	3.2	95
241	Relationship between plasma desipramine levels, CYP2D6 phenotype and clinical response to desipramine: a prospective study. <i>European Journal of Clinical Pharmacology</i> , 1997 , 51, 395-8	2.8	93
240	Sertindole: pharmacological and clinical profile and role in the treatment of schizophrenia. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2008 , 4, 629-38	5.5	91
239	Clinical significance of pharmacokinetic interactions between antiepileptic and psychotropic drugs. <i>Epilepsia</i> , 2002 , 43 Suppl 2, 37-44	6.4	91
238	Inhibition of desmethylimipramine 2-hydroxylation by drugs in human liver microsomes. <i>Biochemical Pharmacology</i> , 1985 , 34, 2501-5	6	91
237	Phenotypic consistency in hydroxylation of desmethylimipramine and debrisoquine in healthy subjects and in human liver microsomes. <i>Clinical Pharmacology and Therapeutics</i> , 1984 , 36, 677-82	6.1	90
236	Effect of aripiprazole augmentation of serotonin reuptake inhibitors or clomipramine in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study. <i>Journal of Clinical Psychopharmacology</i> , 2011 , 31, 174-9	1.7	84
235	Antipsychotic-induced extrapyramidal symptoms in patients with schizophrenia: associations with dopamine and serotonin receptor and transporter polymorphisms. <i>European Journal of Clinical Pharmacology</i> , 2007 , 63, 233-41	2.8	84
234	The effect of lamotrigine augmentation of clozapine in a sample of treatment-resistant schizophrenic patients: a double-blind, placebo-controlled study. <i>Schizophrenia Research</i> , 2007 , 93, 109-16	3.6	84
233	Influence of CYP2C9, 2C19 and 2D6 genetic polymorphisms on the steady-state plasma concentrations of the enantiomers of fluoxetine and norfluoxetine. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2005 , 97, 296-301	3.1	84
232	CYP2D6 genotype and antipsychotic-induced extrapyramidal side effects in schizophrenic patients. <i>European Journal of Clinical Pharmacology</i> , 2000 , 56, 679-83	2.8	82
231	Inhibition of diazepam metabolism by fluvoxamine: a pharmacokinetic study in normal volunteers. <i>Clinical Pharmacology and Therapeutics</i> , 1994 , 56, 471-6	6.1	82
230	Inhibition of risperidone metabolism by fluoxetine in patients with schizophrenia: a clinically relevant pharmacokinetic drug interaction. <i>Journal of Clinical Psychopharmacology</i> , 2002 , 22, 419-23	1.7	80
229	Use of antipsychotics in elderly patients with dementia: do atypical and conventional agents have a similar safety profile?. <i>Pharmacological Research</i> , 2009 , 59, 1-12	10.2	78
228	Antidepressant drugs and seizure susceptibility: from in vitro data to clinical practice. <i>Epilepsia</i> , 1999 , 40 Suppl 10, S48-56	6.4	78

227	Risperidone treatment of children with autistic disorder: effectiveness, tolerability, and pharmacokinetic implications. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2004 , 14, 39-47	2.9	75
226	Adjunctive fluoxetine in the treatment of negative symptoms in chronic schizophrenic patients. <i>International Clinical Psychopharmacology</i> , 1994 , 9, 281-5	2.2	75
225	Lamotrigine augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study. <i>Journal of Psychopharmacology</i> , 2012 , 26, 1456-62	4.6	74
224	Risk of stroke with typical and atypical anti-psychotics: a retrospective cohort study including unexposed subjects. <i>Journal of Psychopharmacology</i> , 2008 , 22, 39-46	4.6	74
223	Determination of risperidone and its major metabolite 9-hydroxyrisperidone in human plasma by reversed-phase liquid chromatography with ultraviolet detection. <i>Biomedical Applications</i> , 2000 , 746, 173-81		72
222	Clinically relevant interactions between newer antidepressants and second-generation antipsychotics. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2014 , 10, 721-46	5.5	70
221	Effect of aripiprazole augmentation of clozapine in schizophrenia: a double-blind, placebo-controlled study. <i>Schizophrenia Research</i> , 2011 , 127, 93-9	3.6	70
220	Estimating the size of the effects of co-medications on plasma clozapine concentrations using a model that controls for clozapine doses and confounding variables. <i>Pharmacopsychiatry</i> , 2008 , 41, 81-91 ²		70
219	Prescribing patterns of antiepileptic drugs in Italy: a nationwide population-based study in the years 2000-2005. <i>European Journal of Neurology</i> , 2007 , 14, 1317-21	6	70
218	Interaction between fluvoxamine and imipramine/desipramine in four patients. <i>Therapeutic Drug Monitoring</i> , 1992 , 14, 194-6	3.2	70
217	Small effects of valproic acid on the plasma concentrations of clozapine and its major metabolites in patients with schizophrenic or affective disorders. <i>Therapeutic Drug Monitoring</i> , 1999 , 21, 341-5	3.2	70
216	The effect of mirtazapine augmentation of clozapine in the treatment of negative symptoms of schizophrenia: a double-blind, placebo-controlled study. <i>International Clinical Psychopharmacology</i> , 2004 , 19, 71-6	2.2	67
215	Inhibition of desipramine 2-hydroxylation by quinidine and quinine. <i>Clinical Pharmacology and Therapeutics</i> , 1988 , 43, 577-81	6.1	65
214	The economic burden of preventable adverse drug reactions: a systematic review of observational studies. <i>Expert Opinion on Drug Safety</i> , 2018 , 17, 681-695	4.1	65
213	Melatonin treatment mimics the antidepressant action in chronic corticosterone-treated mice. <i>Journal of Pineal Research</i> , 2010 , 49, 123-9	10.4	64
212	Debrisoquine oxidation phenotype during neuroleptic monotherapy. <i>European Journal of Clinical Pharmacology</i> , 1991 , 41, 467-70	2.8	60
211	Clinically significant pharmacokinetic drug interactions of antiepileptic drugs with new antidepressants and new antipsychotics. <i>Pharmacological Research</i> , 2016 , 106, 72-86	10.2	59
210	Genetic polymorphisms of cytochrome P450 enzymes and antidepressant metabolism. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2011 , 7, 1101-15	5.5	59

209	Metabolic drug interactions between antidepressants and anticancer drugs: focus on selective serotonin reuptake inhibitors and hypericum extract. <i>Current Drug Metabolism</i> , 2011 , 12, 570-7	3.5	59
208	Plasma concentrations of clozapine and its major metabolites during combined treatment with paroxetine or sertraline. <i>Pharmacopsychiatry</i> , 2000 , 33, 213-7	2	59
207	Severe phenytoin intoxication in a subject homozygous for CYP2C9*3. <i>Clinical Pharmacology and Therapeutics</i> , 2001 , 70, 391-4	6.1	59
206	Generalized versus partial reflex seizures: a review. <i>Seizure: the Journal of the British Epilepsy Association</i> , 2014 , 23, 512-20	3.2	58
205	Adverse Drug Reactions in Hospitalized Patients: Results of the FORWARD (Facilitation of Reporting in Hospital Ward) Study. <i>Frontiers in Pharmacology</i> , 2018 , 9, 350	5.6	57
204	Further evidence for the association between 5-HT _{2C} receptor gene polymorphisms and extrapyramidal side effects in male schizophrenic patients. <i>European Journal of Clinical Pharmacology</i> , 2008 , 64, 477-82	2.8	57
203	Effect of fluoxetine on the plasma concentrations of clozapine and its major metabolites in patients with schizophrenia. <i>International Clinical Psychopharmacology</i> , 1998 , 13, 141-5	2.2	57
202	Assessing drug-drug interactions through therapeutic drug monitoring when administering oral second-generation antipsychotics. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2016 , 12, 407-22	5.5	56
201	Clinical pharmacokinetics of fluvoxamine. <i>Clinical Pharmacokinetics</i> , 1994 , 27, 175-90	6.2	56
200	Pharmacogenetics of antidepressants. <i>Frontiers in Pharmacology</i> , 2011 , 2, 6	5.6	55
199	Antipsychotics and torsadogenic risk: signals emerging from the US FDA Adverse Event Reporting System database. <i>Drug Safety</i> , 2013 , 36, 467-79	5.1	53
198	Antidepressant drugs: prevalence, incidence and indication of use in general practice of Southern Italy during the years 2003-2004. <i>Pharmacoepidemiology and Drug Safety</i> , 2007 , 16, 552-9	2.6	52
197	Clobazam therapeutic drug monitoring: a comprehensive review of the literature with proposals to improve future studies. <i>Therapeutic Drug Monitoring</i> , 2013 , 35, 30-47	3.2	51
196	ABCB1 polymorphisms influence steady-state plasma levels of 9-hydroxyrisperidone and risperidone active moiety. <i>Therapeutic Drug Monitoring</i> , 2008 , 30, 628-33	3.2	51
195	Polymorphic debrisoquine oxidation and acute neuroleptic-induced adverse effects. <i>European Journal of Clinical Pharmacology</i> , 1992 , 42, 347-8	2.8	50
194	Olanzapine augmentation of paroxetine-refractory obsessive-compulsive disorder. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2003 , 27, 619-23	5.5	48
193	Antipsychotic prescribing pattern among Italian general practitioners: a population-based study during the years 1999-2002. <i>European Journal of Clinical Pharmacology</i> , 2005 , 61, 47-53	2.8	48
192	Antidepressant use in the elderly: the role of pharmacodynamics and pharmacokinetics in drug safety. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2015 , 11, 883-92	5.5	46

191	Cytochrome P450 polymorphisms and response to antipsychotic therapy. <i>Pharmacogenomics</i> , 2002 , 3, 201-18	2.6	46
190	Interactions between antiepileptics and second-generation antipsychotics. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2012 , 8, 311-34	5.5	45
189	Hydroxylation of desmethylimipramine: dependence on the debrisoquin hydroxylation phenotype. <i>Clinical Pharmacology and Therapeutics</i> , 1987 , 41, 314-9	6.1	44
188	Genetics of reflex seizures and epilepsies in humans and animals. <i>Epilepsy Research</i> , 2016 , 121, 47-54	3	43
187	Ziprasidone and amisulpride effectively treat negative symptoms of schizophrenia: results of a 12-week, double-blind study. <i>International Clinical Psychopharmacology</i> , 2006 , 21, 143-51	2.2	43
186	Continuous apomorphine infusion (CAI) and neuropsychiatric disorders in patients with advanced Parkinson's disease: a follow-up of two years. <i>Archives of Gerontology and Geriatrics</i> , 2004 , 291-6	4	42
185	Carbamazepine coadministration with fluoxetine or fluvoxamine. <i>Therapeutic Drug Monitoring</i> , 1993 , 15, 247-50	3.2	42
184	A comprehensive review of the clinical utility of and a combined analysis of the clozapine/norclozapine ratio in therapeutic drug monitoring for adult patients. <i>Expert Review of Clinical Pharmacology</i> , 2019 , 12, 603-621	3.8	41
183	A systematic review and combined analysis of therapeutic drug monitoring studies for long-acting risperidone. <i>Expert Review of Clinical Pharmacology</i> , 2017 , 10, 965-981	3.8	41
182	Improved enantioselective assay for the determination of fluoxetine and norfluoxetine enantiomers in human plasma by liquid chromatography. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2003 , 784, 375-83	3.2	41
181	Can valproic acid be an inducer of clozapine metabolism?. <i>Pharmacopsychiatry</i> , 2014 , 47, 89-96	2	39
180	Hypericum perforatum treatment: effect on behaviour and neurogenesis in a chronic stress model in mice. <i>BMC Complementary and Alternative Medicine</i> , 2011 , 11, 7	4.7	39
179	Differences in the inhibitory effect of cimetidine on desipramine metabolism between rapid and slow debrisoquin hydroxylators. <i>Clinical Pharmacology and Therapeutics</i> , 1987 , 42, 278-82	6.1	39
178	Prescribing pattern of anti-epileptic drugs in an Italian setting of elderly outpatients: a population-based study during 2004-07. <i>British Journal of Clinical Pharmacology</i> , 2010 , 70, 514-22	3.8	38
177	Quetiapine versus clozapine: a preliminary report of comparative effects on dopaminergic psychosis in patients with Parkinson's disease. <i>Neurological Sciences</i> , 2002 , 23 Suppl 2, S89-90	3.5	38
176	Estimating the effects of co-medications on plasma olanzapine concentrations by using a mixed model. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2008 , 32, 1453-8	5.5	37
175	Effect of adjunctive lamotrigine treatment on the plasma concentrations of clozapine, risperidone and olanzapine in patients with schizophrenia or bipolar disorder. <i>Therapeutic Drug Monitoring</i> , 2006 , 28, 599-602	3.2	37
174	Lack of a pharmacokinetic interaction between mirtazapine and the newer antipsychotics clozapine, risperidone and olanzapine in patients with chronic schizophrenia. <i>Pharmacological Research</i> , 2003 , 48, 411-4	10.2	36

173	Pharmacokinetic and pharmacodynamic interactions between antiepileptics and antidepressants. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2014 , 10, 1457-89	5.5	35
172	Evaluation of the role of MAPK1 and CREB1 polymorphisms on treatment resistance, response and remission in mood disorder patients. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2013 , 44, 271-8	5.5	35
171	Determination of clozapine, desmethylclozapine and clozapine N-oxide in human plasma by reversed-phase high-performance liquid chromatography with ultraviolet detection. <i>Biomedical Applications</i> , 1998 , 714, 299-308		35
170	The pharmacology and safety of paliperidone extended-release in the treatment of schizophrenia. <i>Expert Opinion on Drug Safety</i> , 2007 , 6, 651-62	4.1	35
169	Plasma concentrations of risperidone and olanzapine during coadministration with oxcarbazepine. <i>Epilepsia</i> , 2005 , 46, 771-4	6.4	35
168	Plasma concentrations of the enantiomers of fluoxetine and norfluoxetine: sources of variability and preliminary observations on relations with clinical response. <i>Therapeutic Drug Monitoring</i> , 2002 , 24, 616-27	3.2	35
167	Effect of ketoconazole on the pharmacokinetics of imipramine and desipramine in healthy subjects. <i>British Journal of Clinical Pharmacology</i> , 1997 , 43, 315-8	3.8	34
166	Newer and older antiepileptic drug use in Southern Italy: a population-based study during the years 2003-2005. <i>Epilepsy Research</i> , 2009 , 85, 107-13	3	33
165	Short- and long-term effects on prolactin of risperidone and olanzapine treatments in children and adolescents. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2009 , 33, 1496-501	5.5	33
164	Effect of valproate on olanzapine plasma concentrations in patients with bipolar or schizoaffective disorder. <i>Therapeutic Drug Monitoring</i> , 2009 , 31, 758-63	3.2	33
163	Short-term memory loss associated with rosuvastatin. <i>Pharmacotherapy</i> , 2006 , 26, 1190-2	5.8	32
162	Are the safety profiles of antipsychotic drugs used in dementia the same? An updated review of observational studies. <i>Drug Safety</i> , 2014 , 37, 501-20	5.1	31
161	Determination of olanzapine in human plasma by reversed-phase high-performance liquid chromatography with ultraviolet detection. <i>Therapeutic Drug Monitoring</i> , 2006 , 28, 388-93	3.2	31
160	Adverse drug interaction between risperidone and carbamazepine in a patient with chronic schizophrenia and deficient CYP2D6 activity. <i>Journal of Clinical Psychopharmacology</i> , 2001 , 21, 108-9	1.7	30
159	Phenobarbital induces the 2-hydroxylation of desipramine. <i>Therapeutic Drug Monitoring</i> , 1996 , 18, 60-4	3.2	30
158	The Effect of Safety Warnings on Antipsychotic Drug Prescribing in Elderly Persons with Dementia in the United Kingdom and Italy: A Population-Based Study. <i>CNS Drugs</i> , 2016 , 30, 1097-1109	6.7	29
157	Inducing effect of phenobarbital on clozapine metabolism in patients with chronic schizophrenia. <i>Therapeutic Drug Monitoring</i> , 1998 , 20, 628-30	3.2	29
156	A comprehensive review of swallowing difficulties and dysphagia associated with antipsychotics in adults. <i>Expert Review of Clinical Pharmacology</i> , 2019 , 12, 219-234	3.8	29

155	Clozapine Metabolism in East Asians and Caucasians: A Pilot Exploration of the Prevalence of Poor Metabolizers and a Systematic Review. <i>Journal of Clinical Psychopharmacology</i> , 2019 , 39, 135-144	1.7	29
154	Clinically relevant drug interactions in anxiety disorders. <i>Human Psychopharmacology</i> , 2012 , 27, 239-53	2.3	28
153	Duloxetine as adjunctive treatment to clozapine in patients with schizophrenia: a randomized, placebo-controlled trial. <i>International Clinical Psychopharmacology</i> , 2011 , 26, 303-10	2.2	28
152	Melatonin β stimulatory effect on adult hippocampal neurogenesis in mice persists after ovariectomy. <i>Journal of Pineal Research</i> , 2011 , 51, 353-60	10.4	27
151	Interaction of carbamazepine-10,11-epoxide, an active metabolite of carbamazepine, with valproate: a pharmacokinetic study. <i>Epilepsia</i> , 1990 , 31, 339-42	6.4	27
150	Clinical trial methodology to assess the efficacy/effectiveness of long-acting antipsychotics: Randomized controlled trials vs naturalistic studies. <i>Psychiatry Research</i> , 2017 , 247, 257-264	9.9	26
149	Indications of newer and older anti-epileptic drug use: findings from a southern Italian general practice setting from 2005-2011. <i>British Journal of Clinical Pharmacology</i> , 2015 , 79, 1010-9	3.8	26
148	Pharmacokinetic optimisation of tricyclic antidepressant therapy. <i>Clinical Pharmacokinetics</i> , 1993 , 24, 301-18	6.2	26
147	A systematic review and combined analysis of therapeutic drug monitoring studies for long-acting paliperidone. <i>Expert Review of Clinical Pharmacology</i> , 2018 , 11, 1237-1253	3.8	26
146	A systematic review and combined analysis of therapeutic drug monitoring studies for oral paliperidone. <i>Expert Review of Clinical Pharmacology</i> , 2018 , 11, 625-639	3.8	26
145	Changes in the prescribing pattern of antidepressant drugs in elderly patients: an Italian, nationwide, population-based study. <i>European Journal of Clinical Pharmacology</i> , 2014 , 70, 469-78	2.8	25
144	Prescribing pattern of anti-Parkinson drugs in Southern Italy: cross-sectional analysis in the years 2003-2005. <i>Parkinsonism and Related Disorders</i> , 2008 , 14, 420-5	3.6	25
143	A nationwide prospective study on prescribing pattern of antidepressant drugs in Italian primary care. <i>European Journal of Clinical Pharmacology</i> , 2013 , 69, 227-36	2.8	24
142	Plasma risperidone concentrations during combined treatment with sertraline. <i>Therapeutic Drug Monitoring</i> , 2004 , 26, 386-90	3.2	24
141	The effect of carbamazepine on the 2-hydroxylation of desipramine. <i>Psychopharmacology</i> , 1995 , 117, 413-6	4.7	24
140	Single dose pharmacokinetics of carbamazepine-10,11-epoxide in patients on lamotrigine monotherapy. <i>Epilepsy Research</i> , 1994 , 19, 245-8	3	24
139	Safety profiles of biologic agents for inflammatory bowel diseases: a prospective pharmacovigilance study in Southern Italy. <i>Current Medical Research and Opinion</i> , 2020 , 36, 1457-1463	2.5	23
138	Possible Pharmacodynamic and Pharmacokinetic Drug-Drug Interactions That Are Likely to Be Clinically Relevant and/or Frequent in Bipolar Disorder. <i>Current Psychiatry Reports</i> , 2018 , 20, 17	9.1	23

137	Effect of valpromide on the pharmacokinetics of carbamazepine-10, 11-epoxide. <i>British Journal of Clinical Pharmacology</i> , 1988 , 25, 611-3	3.8	23
136	Elevation of plasma carbamazepine concentrations by ketoconazole in patients with epilepsy. <i>Therapeutic Drug Monitoring</i> , 1997 , 19, 535-8	3.2	23
135	Progress and prospects in pharmacogenetics of antidepressant drugs. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2016 , 12, 1157-68	5.5	22
134	Management of women with epilepsy: from preconception to post-partum. <i>Archives of Gynecology and Obstetrics</i> , 2016 , 293, 493-503	2.5	22
133	No Effect of Citalopram on Plasma Levels of Clozapine, Risperidone and their Active Metabolites in Patients with Chronic Schizophrenia. <i>Clinical Drug Investigation</i> , 1998 , 16, 393-398	3.2	22
132	Debrisoquine oxidation phenotype and neuroleptic-induced dystonic reactions. <i>Acta Psychiatrica Scandinavica</i> , 1992 , 86, 364-6	6.5	22
131	Carbamazepine induced bradycardia--a problem in general or only in susceptible patients? A 24-h long-term electrocardiogram study. <i>Epilepsy Research</i> , 1992 , 13, 141-5	3	22
130	Head-to-Head Comparison of Aripiprazole and Risperidone in the Treatment of ADHD Symptoms in Children with Autistic Spectrum Disorder and ADHD: A Pilot, Open-Label, Randomized Controlled Study. <i>Paediatric Drugs</i> , 2016 , 18, 319-29	4.2	21
129	Augmentation of clozapine with ziprasidone in refractory schizophrenia: a double-blind, placebo-controlled study. <i>Journal of Clinical Psychopharmacology</i> , 2014 , 34, 129-33	1.7	21
128	Restless Leg Syndrome in ADHD children: levetiracetam as a reasonable therapeutic option. <i>Brain and Development</i> , 2011 , 33, 480-6	2.2	21
127	No effect of the new antidepressant reboxetine on CYP2D6 activity in healthy volunteers. <i>Therapeutic Drug Monitoring</i> , 1999 , 21, 577-9	3.2	21
126	Prevalence of acute dystonic reactions associated with neuroleptic treatment with and without anticholinergic prophylaxis. <i>International Clinical Psychopharmacology</i> , 1993 , 8, 21-4	2.2	20
125	Neuropsychiatric reactions to drugs: an analysis of spontaneous reports from general practitioners in Italy. <i>Pharmacological Research</i> , 2005 , 51, 211-6	10.2	19
124	ECG parameters in children and adolescents treated with aripiprazole and risperidone. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2014 , 51, 23-7	5.5	18
123	Use and tolerability of newer antipsychotics and antidepressants: a chart review in a paediatric setting. <i>International Journal of Clinical Pharmacy</i> , 2008 , 30, 44-50		18
122	No effect of reboxetine on plasma concentrations of clozapine, risperidone, and their active metabolites. <i>Therapeutic Drug Monitoring</i> , 2001 , 23, 675-8	3.2	18
121	Oxidation of tricyclic antidepressant drugs, debrisoquine and 7-ethoxyresorufin, by human liver preparations. <i>Xenobiotica</i> , 1986 , 16, 391-400	2	18
120	Tricyclic Antidepressants Analysis by Liquid Chromatography. <i>Journal of Liquid Chromatography and Related Technologies</i> , 1987 , 10, 223-240		18

119	Single-Dose Kinetics of an Enteric-Coated Formulation of Carbamazepine-10,11-epoxide, an Active Metabolite of Carbamazepine. <i>Therapeutic Drug Monitoring</i> , 1988 , 10, 386-389	3.2	18
118	Glutamine-supplemented total parenteral nutrition improves immunological status in anorectic patients. <i>Nutrition</i> , 2010 , 26, 677-81	4.8	17
117	Effect of topiramate on plasma concentrations of clozapine, olanzapine, risperidone, and quetiapine in patients with psychotic disorders. <i>Clinical Neuropharmacology</i> , 2007 , 30, 107-13	1.4	17
116	n-3 fatty acids prevent impairment of neurogenesis and synaptic plasticity in B-cell activating factor (BAFF) transgenic mice. <i>Preventive Medicine</i> , 2012 , 54 Suppl, S103-8	4.3	16
115	Drug dosage individualization based on a random-effects linear model. <i>Journal of Biopharmaceutical Statistics</i> , 2012 , 22, 463-84	1.3	16
114	CYP2D6-related oxidation polymorphism in Italy. <i>Pharmacological Research</i> , 1994 , 29, 281-9	10.2	16
113	Newer and Older Antidepressants. <i>CNS Drugs</i> , 1994 , 2, 479-497	6.7	16
112	In vitro inhibition of a polymorphic human liver P-450 isozyme by narcotic analgesics. <i>Anesthesiology</i> , 1989 , 70, 339-42	4.3	16
111	Fluvoxamine-induced alterations in plasma concentrations of imipramine and desipramine in depressed patients. <i>International Journal of Clinical Pharmacology Research</i> , 1993 , 13, 167-71		16
110	Pharmacokinetics of the antidepressant drug viloxazine in normal subjects and in epileptic patients receiving chronic anticonvulsant treatment. <i>Psychopharmacology</i> , 1986 , 90, 295-8	4.7	15
109	Differential effects of cimetidine and ranitidine on imipramine demethylation and desmethylimipramine hydroxylation by human liver microsomes. <i>European Journal of Clinical Pharmacology</i> , 1986 , 30, 239-42	2.8	15
108	6-Mer Hyaluronan Oligosaccharides Modulate Neuroinflammation and β Synuclein Expression in Neuron-Like SH-SY5Y Cells. <i>Journal of Cellular Biochemistry</i> , 2016 , 117, 2835-2843	4.7	15
107	A molecular pathway analysis informs the genetic background at risk for schizophrenia. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2015 , 59, 21-30	5.5	14
106	Pharmaco-utilisation and related costs of drugs used to treat schizophrenia and bipolar disorder in Italy: the IBIS study. <i>BMC Psychiatry</i> , 2014 , 14, 282	4.2	14
105	How frequently are contraindicated or warned against combinations of drugs prescribed to patients receiving long-term opioid therapy for chronic pain?. <i>Pharmacoepidemiology and Drug Safety</i> , 2012 , 21, 453-62	2.6	14
104	Clinically relevant drug interactions between newer antidepressants and oral anticoagulants. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2020 , 16, 31-44	5.5	14
103	Effect of fluvoxamine on plasma risperidone concentrations in patients with schizophrenia. <i>Pharmacological Research</i> , 2005 , 52, 497-501	10.2	13
102	No association between CYP2D6 polymorphism and Alzheimer's disease in an Italian population. <i>Pharmacological Research</i> , 2006 , 53, 162-5	10.2	13

101	Assessment and Management of Cognitive and Psychosocial Dysfunctions in Patients With Major Depressive Disorder: A Clinical Review. <i>Frontiers in Psychiatry</i> , 2018 , 9, 493	5	13
100	Rabeprazole and psychiatric symptoms. <i>Annals of Pharmacotherapy</i> , 2007 , 41, 1315-7	2.9	12
99	Pharmacogenetic aspects in the metabolism of psychotropic drugs: pharmacokinetic and clinical implications. <i>Pharmacological Research</i> , 1994 , 29, 121-37	10.2	12
98	Effect of phenobarbital on the pharmacokinetics of carbamazepine-10,11-epoxide, an active metabolite of carbamazepine. <i>Therapeutic Drug Monitoring</i> , 1991 , 13, 109-12	3.2	12
97	Debrisoquine oxidation in an Italian population: a study in healthy subjects and in schizophrenic patients. <i>Pharmacological Research</i> , 1992 , 25, 43-50	10.2	12
96	The Role of Levomilnacipran in the Management of Major Depressive Disorder: A Comprehensive Review. <i>Current Neuropharmacology</i> , 2016 , 14, 191-9	7.6	12
95	Clinically relevant drug interactions between statins and antidepressants. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2020 , 45, 227-239	2.2	12
94	Safety and efficacy of paliperidone extended-release in acute and maintenance treatment of schizophrenia. <i>Journal of Central Nervous System Disease</i> , 2011 , 3, 27-41	4.4	11
93	Newer antipsychotics: comparative review of drug interactions. <i>Expert Review of Neurotherapeutics</i> , 2001 , 1, 171-82	4.3	11
92	Alprazolam does not inhibit the metabolism of nortriptyline in depressed patients or inhibit the metabolism of desipramine in human liver microsomes. <i>Therapeutic Drug Monitoring</i> , 1988 , 10, 231-3	3.2	11
91	Interaction between fluoxetine and haloperidol: pharmacokinetic and clinical implications. <i>Pharmacological Research</i> , 1997 , 35, 335-9	10.2	11
90	An International Adult Guideline for Making Clozapine Titration Safer by Using Six Ancestry-Based Personalized Dosing Titrations, CRP, and Clozapine Levels. <i>Pharmacopsychiatry</i> , 2021 , 55,	2	11
89	Ototoxic Adverse Drug Reactions: A Disproportionality Analysis Using the Italian Spontaneous Reporting Database. <i>Frontiers in Pharmacology</i> , 2019 , 10, 1161	5.6	10
88	Evaluation of acute cardiovascular effects of immediate-release methylphenidate in children and adolescents with attention-deficit hyperactivity disorder. <i>Neuropsychiatric Disease and Treatment</i> , 2015 , 11, 1169-74	3.1	10
87	Augmentation of clozapine with agomelatine in partial-responder schizophrenia: a 16-week, open-label, uncontrolled pilot study. <i>Journal of Clinical Psychopharmacology</i> , 2014 , 34, 491-4	1.7	10
86	Potentially Clinically Relevant Pharmacodynamic Interactions Between Antiepileptic Drugs and Psychotropic Drugs: An Update. <i>Current Pharmaceutical Design</i> , 2017 , 23, 5625-5638	3.3	10
85	Preclinical data supporting/refuting the use of Hypericum perforatum in the treatment of depression. <i>CNS and Neurological Disorders - Drug Targets</i> , 2013 , 12, 474-86	2.6	10
84	Pharmacokinetic drug-drug interactions between olanzapine and valproate need to be better studied. <i>Journal of Clinical Psychiatry</i> , 2010 , 71, 957-8; author reply 958-9	4.6	10

83	Low-Dose of Bergamot-Derived Polyphenolic Fraction (BPF) Did Not Improve Metabolic Parameters in Second Generation Antipsychotics-Treated Patients: Results from a 60-days Open-Label Study. <i>Frontiers in Pharmacology</i> , 2017 , 8, 197	5.6	9
82	Effects of L'Aquila earthquake on the prescribing pattern of antidepressant and antipsychotic drugs. <i>International Journal of Clinical Pharmacy</i> , 2013 , 35, 1053-62	2.3	9
81	Urinary desipramine hydroxylation index and steady-state plasma concentrations of imipramine and desipramine. <i>Therapeutic Drug Monitoring</i> , 1987 , 9, 129-33	3.2	9
80	Duloxetine in Psychiatric Disorders: Expansions Beyond Major Depression and Generalized Anxiety Disorder. <i>Frontiers in Psychiatry</i> , 2019 , 10, 772	5	9
79	Co-prescriptions with itraconazole and fluconazole as a signal for possible risk of drug-drug interactions: a four-year analysis from Italian general practice. <i>Pharmacoepidemiology and Drug Safety</i> , 2007 , 16, 422-8	2.6	8
78	Venlafaxine-induced urinary incontinence resolved after switching to sertraline. <i>Clinical Neuropharmacology</i> , 2005 , 28, 247-8	1.4	8
77	Minor additive inducing effects of phenobarbital on carbamazepine clearance in patients on combined carbamazepine-phenytoin therapy. <i>Therapeutic Drug Monitoring</i> , 1987 , 9, 117-9	3.2	8
76	Clinically Relevant Drug Interactions with Anti-Alzheimer's Drugs. <i>CNS and Neurological Disorders - Drug Targets</i> , 2017 , 16, 501-513	2.6	8
75	High mobility group box 1 and markers of oxidative stress in human cord blood. <i>Pediatrics International</i> , 2019 , 61, 264-270	1.2	7
74	Generic Olanzapine Substitution in Patients With Schizophrenia: Assessment of Serum Concentrations and Therapeutic Response After Switching. <i>Therapeutic Drug Monitoring</i> , 2015 , 37, 827-30 ²	3.2	7
73	Acute cerebellar ataxia following meningococcal group C conjugate vaccination. <i>Journal of Child Neurology</i> , 2014 , 29, 128-30	2.5	7
72	Analysis of tricyclic antidepressants in serum and plasma yields similar results. <i>Therapeutic Drug Monitoring</i> , 1985 , 7, 242-3	3.2	7
71	Evidence of chromosomal fragile sites in schizophrenic patients. <i>Annales De Génétique</i> , 1993 , 36, 132-5		7
70	Therapeutic Drug Monitoring of Quetiapine: Effect of Coadministration with Antiepileptic Drugs in Patients with Psychiatric Disorders. <i>The Open Clinical Chemistry Journal</i> , 2008 , 1, 17-21		7
69	Issues in methodology and applications for therapeutic drug monitoring of fluoxetine and norfluoxetine enantiomers. <i>Therapeutic Drug Monitoring</i> , 1998 , 20, 20-4	3.2	7
68	Real World Data on the Utilization Pattern and Safety Profile of Infliximab Originator Versus Biosimilars in Italy: A Multiregional Study. <i>BioDrugs</i> , 2018 , 32, 607-617	7.9	7
67	Clinically Relevant Interactions between Atypical Antipsychotics and Anti-Infective Agents. <i>Pharmaceuticals</i> , 2020 , 13,	5.2	6
66	Pharmacogenetics of drug-metabolizing enzymes in Italian populations. <i>Drug Metabolism and Personalized Therapy</i> , 2015 , 30, 107-20	2	6

65	Effect of adjunctive duloxetine on the plasma concentrations of clozapine, olanzapine, and risperidone in patients with psychotic disorders. <i>Journal of Clinical Psychopharmacology</i> , 2010 , 30, 634-6	1.7	6
64	The effect of clozapine on aggressive behaviour in patients with chronic schizophrenia. <i>International Journal of Psychiatry in Clinical Practice</i> , 1999 , 3, 49-54	2.4	6
63	Diazepam treatment does not influence the debrisoquine or mephenytoin hydroxylation phenotyping tests. <i>Therapeutic Drug Monitoring</i> , 1989 , 11, 721-3	3.2	6
62	European Whites May Need Lower Minimum Therapeutic Clozapine Doses Than Those Customarily Proposed. <i>Journal of Clinical Psychopharmacology</i> , 2021 , 41, 140-147	1.7	6
61	Evaluation of putative cytotoxic activity of crude extracts from <i>Onopordum acanthium</i> leaves and <i>Spartium junceum</i> flowers against the U-373 glioblastoma cell line. <i>Pakistan Journal of Pharmaceutical Sciences</i> , 2015 , 28, 1225-32	0.4	6
60	Red Yeast Rice (RYR) supplementation in patients treated with second-generation antipsychotics. <i>Complementary Therapies in Medicine</i> , 2018 , 37, 167-171	3.5	5
59	Rapid versus slow withdrawal of antiepileptic monotherapy in 2-year seizure-free adult patients with epilepsy (RASLOW) study: a pragmatic multicentre, prospective, randomized, controlled study. <i>Neurological Sciences</i> , 2016 , 37, 579-83	3.5	5
58	Predictability of metabolic antiepileptic drug interactions 2005 , 57-92		5
57	No effect of thioridazine on plasma concentrations of carbamazepine and its active metabolite carbamazepine-10,11-epoxide. <i>Therapeutic Drug Monitoring</i> , 1990 , 12, 511-3	3.2	5
56	Evaluation of tricyclic antidepressant plasma levels by an automated enzyme immunoassay (EMIT) in comparison to a high-performance liquid chromatographic method. <i>Therapeutic Drug Monitoring</i> , 1988 , 10, 333-9	3.2	5
55	Safety and Tolerability of Antipsychotic Drugs in Pediatric Patients: Data From a 1-Year Naturalistic Study. <i>Frontiers in Psychiatry</i> , 2020 , 11, 152	5	5
54	Drug interactions with vortioxetine, a new multimodal antidepressant. <i>Rivista Di Psichiatria</i> , 2015 , 50, 210-5	3.1	5
53	Characterization and preventability of adverse drug events as cause of emergency department visits: a prospective 1-year observational study. <i>BMC Pharmacology & Toxicology</i> , 2019 , 20, 21	2.6	4
52	Safety Profile of Biologics Used in Rheumatology: An Italian Prospective Pharmacovigilance Study. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	4
51	Long-Term Intravitreal Ranibizumab as a Potential Additional Risk Factor for Neurodegeneration in Parkinson's Disease: A Case Report. <i>Frontiers in Pharmacology</i> , 2018 , 9, 608	5.6	4
50	Iron status in schizophrenic patients with acute neuroleptic-induced dystonic reactions. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 1994 , 18, 891-8	5.5	4
49	Impairment of carbamazepine-10, 11-epoxide elimination by valnoctamide, a valpromide isomer, in healthy subjects. <i>British Journal of Clinical Pharmacology</i> , 1992 , 34, 85-7	3.8	4
48	Epidemiology and pathoetiology of neurological syndromes with hyperthermia. <i>Functional Neurology</i> , 1995 , 10, 111-9	2.2	4

47	Vortioxetine on Cognition in Schizophrenia: A Pilot Study. <i>Journal of Clinical Psychopharmacology</i> , 2020 , 40, 381-385	1.7	3
46	Serenoa repens as an Endocrine Disruptor in a 10-Year-Old Young Girl: A New Case Report. <i>Pharmacology</i> , 2015 , 96, 41-3	2.3	3
45	Reboxetine adjuvant therapy in patients with schizophrenia showing a suboptimal response to clozapine: a 12-week, open-label, pilot study. <i>Journal of Clinical Psychopharmacology</i> , 2014 , 34, 620-3	1.7	3
44	Characterization of desmethylimipramine 2-hydroxylation in human foetal and adult liver microsomes. <i>Acta Pharmacologica Et Toxicologica</i> , 1986 , 58, 277-81		3
43	Effects of valpromide and viloxazine on the elimination of carbamazepine-10,11-epoxide, an active metabolite of carbamazepine. <i>Pharmacological Research</i> , 1989 , 21, 111-2	10.2	3
42	Debrisoquine oxidation in schizophrenic patients treated with neuroleptics. <i>Pharmacological Research Communications</i> , 1988 , 20, 1103-4		3
41	IN VITRO COMPETITIVE INHIBITION OF DESIPRAMINE HYDROXYLATION BY ALFENTANIL AND FENTANYL IN HUMAN LIVER MICROSOMES. <i>Anesthesiology</i> , 1985 , 63, A305	4.3	3
40	Real-world use of biological drugs in patients with psoriasis/psoriatic arthritis: a retrospective, population-based study of years 2010-2014 from Southern Italy. <i>Giornale Italiano Di Dermatologia E Venereologia</i> , 2020 , 155, 441-451	0.8	3
39	Inhibition of desipramine 2-hydroxylation by quinidine and quinine in rapid and slow debrisoquine hydroxylators. <i>Psychopharmacology Series</i> , 1989 , 7, 201-5		3
38	Adverse drug reactions with oral anticoagulants: data from sicilian spontaneous reporting system database. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2021 , 46, 1027-1040	2.2	3
37	Tools for optimising pharmacotherapy in psychiatry (therapeutic drug monitoring, molecular brain imaging and pharmacogenetic tests): focus on antidepressants. <i>World Journal of Biological Psychiatry</i> , 2021 , 22, 561-628	3.8	3
36	Early atypical injection-site reactions to COVID-19 vaccine: a case series. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021 ,	4.6	3
35	Prevalence of primary cutis verticis gyrata in a psychiatric population: association with chromosomal fragile sites. <i>Acta Dermato-Venereologica</i> , 1990 , 70, 483-6	2.2	3
34	Transient global amnesia as a presenting aura or epilepsy?. <i>Headache</i> , 2014 , 54, 1233-5	4.2	2
33	Can zinc depletion play a role in LEV-induced hair loss? Considerations from a case study. <i>Epilepsy and Behavior</i> , 2013 , 29, 254-5	3.2	2
32	Pharmacokinetics of Paliperidone Palmitate in Schizophrenic Patients: Data from a Routine Therapeutic Drug Monitoring Service. <i>Clinical Therapeutics</i> , 2017 , 39, e50-e51	3.5	2
31	Decreased plasma concentrations of imipramine and desipramine following cholestyramine intake in depressed patients. <i>Therapeutic Drug Monitoring</i> , 1994 , 16, 432-4	3.2	2
30	Pharmacokinetic interactions between tricyclic antidepressants and other psychotropic drugs in depressed patients. <i>Pharmacological Research</i> , 1992 , 25, 210-211	10.2	2

29	Valproic acid-amitriptyline interaction in man. <i>Therapeutic Drug Monitoring</i> , 1986 , 8, 382-3	3.2	2
28	Desmethylinipramine overdose: nonlinear kinetics in a slow hydroxylator. <i>Therapeutic Drug Monitoring</i> , 1985 , 7, 239-41	3.2	2
27	Pediatric adverse reactions to antiseizure medications - An analysis of data from the Italian spontaneous reporting system (2001-2019). <i>Epilepsy and Behavior</i> , 2021 , 119, 107989	3.2	2
26	Adverse Drug Reactions with HER2-Positive Breast Cancer Treatment: An Analysis from the Italian Pharmacovigilance Database. <i>Drugs - Real World Outcomes</i> , 2021 , 1	2.2	2
25	Efficacy of Antidepressants: Issues Related to Bias in Clinical Trials. <i>Clinical Therapeutics</i> , 2016 , 38, e2	3.5	1
24	Pharmacogenomics of Depression. <i>Advances in Biological Psychiatry</i> , 2010 , 58-74		1
23	Severe phenytoin intoxication in a subject homozygous for CYP2C9*3. <i>Clinical Pharmacology and Therapeutics</i> , 2001 , 70, 403-404	6.1	1
22	Single-dose kinetics of an enteric-coated formulation of carbamazepine-10,11-epoxide, an active metabolite of carbamazepine. <i>Therapeutic Drug Monitoring</i> , 1988 , 10, 382-5	3.2	1
21	Prevalence of cardiac conduction disturbances during carbamazepine treatment: preliminary data. <i>Functional Neurology</i> , 1987 , 2, 563-7	2.2	1
20	Mood Stabilizers 2016 , 177-203		1
19	Safety profile of immune checkpoint inhibitors: An analysis of the Italian spontaneous reporting system database. <i>British Journal of Clinical Pharmacology</i> , 2021 , 87, 527-541	3.8	1
18	Pharmacokinetic drug interactions with oral haloperidol in adults: dose correction factors from a combined weighted analysis.. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2022 ,	5.5	1
17	An endocrinological study of patients with primary cutis verticis gyrata. <i>Acta Dermato-Venereologica</i> , 1993 , 73, 348-9	2.2	1
16	A Narrative Review on Efficacy and Safety of Proton Pump Inhibitors in Children.. <i>Frontiers in Pharmacology</i> , 2022 , 13, 839972	5.6	0
15	Adverse Drug Reactions with Drugs Used in Multiple Sclerosis: An Analysis from the Italian Pharmacovigilance Database.. <i>Frontiers in Pharmacology</i> , 2022 , 13, 808370	5.6	0
14	Clinical validation of a combinatorial PharmAcogeNomic approach in major Depressive disorder: an Observational prospective RANdomized, participant and rater-blinded, controlled trial (PANDORA trial).. <i>Trials</i> , 2021 , 22, 896	2.8	0
13	Screening the European pharmacovigilance database for reports of clozapine-related DRESS syndrome: 47 novel cases. <i>European Neuropsychopharmacology</i> , 2022 , 60, 25-37	1.2	0
12	P.1.a.016 CHL1 gene: a new promising antidepressant response marker in major depression. <i>European Neuropsychopharmacology</i> , 2013 , 23, S168-S169	1.2	

11	P.1.c.012 Open-label study comparing the efficacy and tolerability of aripiprazole and risperidone in the treatment of children with autism spectrum disorder and ADHD. <i>European Neuropsychopharmacology</i> , 2015 , 25, S200-S201	1.2
10	Aripiprazole in children with multiple-complex developmental disorder (McDD): a case series. <i>European Psychiatry</i> , 2011 , 26, 1284-1284	6
9	New antiepileptic drugs 2011 , 38-52	
8	Reply to Lian et al.. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2010 , 34, 1159	5.5
7	6. Predicting effects of antiepileptics on mood: Clues from knowledge about mechanisms of action. <i>Epilepsy and Behavior</i> , 2010 , 17, 580-581	3.2
6	Preventing drug interactions with antidepressants in the elderly. <i>Aging Health</i> , 2007 , 3, 231-243	
5	Intra-daily oscillations in dipropylacetic acid plasma levels with two or three daily doses of dipropylacetamide in epileptic patients. <i>Italian Journal of Neurological Sciences</i> , 1983 , 4, 173-7	
4	Therapeutic continuity in the treatment of psychiatric disorders. <i>Global & Regional Health Technology Assessment</i> , 2015 , 2, GRHTA.5000197	0.2
3	P481 Effectiveness and safety profile of biological therapy in inflammatory bowel disease: real life data from an active pharmacovigilance project. <i>Journal of Crohns and Colitis</i> , 2021 , 15, S470-S471	1.5
2	EKG parameters in children and adolescents treated with second-generation antipsychotics: a 1-year prospective follow-up study. <i>European Neuropsychopharmacology</i> , 2016 , 26, S745-S746	1.2
1	Biosimilars in Pediatric Inflammatory Bowel Diseases: A Systematic Review and Real Life-Based Evidence.. <i>Frontiers in Pharmacology</i> , 2022 , 13, 846151	5.6